

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

IN RE OZEMPIC (SEMAGLUTIDE) PATENT
LITIGATION

C.A. No. 22-md-3038-CFC

CONFIDENTIAL

NOVO NORDISK INC. AND NOVO
NORDISK A/S,

Plaintiffs/Counterclaim Defendants,

v.

RIO BIOPHARMACEUTICALS INC., et al.,

Defendants/Counterclaim Plaintiffs.

C.A. No. 22-294-CFC

NOVO NORDISK INC. AND NOVO
NORDISK A/S,

Plaintiffs/Counterclaim Defendants,

v.

MYLAN PHARMACEUTICALS INC.,

Defendants/Counterclaim Plaintiffs.

C.A. No. 22-cv-1040-CFC

**Opening Expert Report of Dr. Paul Dalby
Regarding Invalidity of U.S. Patent No. 10,335,462**

TABLE OF CONTENTS

	Page
I. Qualifications and Background	1
A. Education and Experience; Prior Testimony.....	1
B. Basis for Opinions and Materials Considered.....	5
C. Retention and Compensation	6
II. Summary of Opinions.....	6
III. Legal Standards	8
IV. Person of Ordinary Skill in the Art.....	10
V. The '462 Patent And Asserted Claims 4, 5, 7	13
A. The Formulation Claims of the '462 Patent.....	13
B. The Prosecution History of the '462 Patent	14
VI. Claim Construction.....	17
VII. Background on GLP-1 Compound Formulations Used to Treat Diabetes	19
A. Parenteral formulations and components thereof were well- known	19
B. GLP-1 compounds were well-known.....	20
C. GLP-1 agonists and related formulations were well-known.....	23
D. Parenteral dosage forms for peptide-based drugs	23
1. Tonicity and osmolarity of the parenteral formulation.....	25
2. pH and buffering capacity of the parenteral formulation	26
3. Avoiding particulates in the parenteral formulation.....	27
4. Vehicles and diluents of the parenteral formulation.....	27
5. Excipients of the parenteral formulation	28
VIII. Scope and Content of the Prior Art	29
A. WO 2011/138421 (“WO ’421”).....	30
B. Clinical Trial No. NCT00696657 (NCT657).....	31
C. WO 2006/097537 (“WO ’537”).....	33

TABLE OF CONTENTS
(continued)

	Page
D. Lovshin	37
E. U.S. Patent No. 8,114,833 (“’833 patent”)	38
F. Madsbad 2011	39
G. Other Art That Informs the POSA’s Knowledge.....	40
1. U.S. Patent No. 6,268,343 (the “Knudsen patent”)	40
2. Victoza label	42
3. WO 03/002136 (“WO ’136”).....	42
4. Additional prior art and references	44
5. The inventor’s knowledge of the formulation art.....	45
IX. Invalidity of the Claims of the ’462 Patent	45
A. The State of the Art and a POSA’s Background Knowledge	46
B. Claims 4, 5, and 7 of the ’462 patent would have been obvious over WO ’421, NCT657, WO ’537, and/or Lovshin, optionally in view of one or more of the ’833 Patent and Madsbad, in view of the knowledge of a POSA.....	53
1. The dependent limitations of claim 4 would have been obvious	54
2. The dependent limitations of claim 5 would have been obvious	59
3. The dependent limitations of claim 7 would have been obvious	62
4. Conclusion	64
C. Claims 4, 5, and 7 of the ’462 patent would have been obvious over WO ’421 alone or in view of the ’833 patent	65
D. Claims 4, 5, and 7 of the ’462 patent would have been obvious over WO ’537 considering Lovshin.....	68
X. Reservation of Rights	69

TABLE OF ABBREVIATIONS

Full Name of Cited Reference	Abbreviation
U.S. Patent No. 5,164,366	'366 patent
U.S. Patent No. 10,335,462	'462 patent
U.S. Patent No. 7,022,674	'674 patent
U.S. Patent No. 6,284,727	'727 patent
U.S. Patent No. 8,114,833	'833 patent
U.S. Patent No. 6,458,924	'924 patent
Deposition of Christine Jensen, M.D., Ph.D. (Nov. 8, 2023)	Jensen Dep.
Knudsen, <i>Glucagon-Like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes</i> , 47 J. MED. CHEM. 4128 (2004)	Knudsen 2004
U.S. Patent No. 6,268,343	Knudsen patent
Lovshin, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus</i> , 5 NATURE REVIEWS ENDOCRINOLOGY 262 (2009)	Lovshin
Lund, <i>Emerging GLP-1 Receptor Agonists</i> , 16 EXPERT OPINION ON EMERGING DRUGS 607 (2011)	Lund
Madsbad et al., <i>An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists—Available Efficacy and Safety Data and Perspectives for the Future</i> , 13 DIABETES, OBESITY & METABOLISM, 394 (2011)	Madsbad 2011
Boylan, <i>Parenteral Products</i> , in MODERN PHARMACEUTICS (Gilbert S. Banker et al. eds., 3d ed. 1996)	Modern Pharmaceutics
Clinical Trial No. NCT00696657	NCT657
Ozempic prescribing information (Oct. 2022)	Ozempic label
REMYNTOX: THE SCIENCE AND PRACTICE OF PHARMACY (Alfonso R. Gennaro ed., 20th ed. 2000)	Remington
<i>Victoza</i> , PHYSICIANS' DESK REFERENCE (65th ed. 2010)	Victoza label
WO 00/37098	WO '098
WO 03/002136	WO '136
WO 2011/058193	WO '193

TABLE OF ABBREVIATIONS
(continued)

Full Name of Cited Reference	Abbreviation
WO 2011/073328	WO '328
WO 2011/138421	WO '421
WO 2006/097537	WO '537

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.